Skip to Content
You are currently on the new version of our website. Access the old version .
Hematology ReportsHematology Reports
  • Case Report
  • Open Access

19 June 2014

2 Pages

Development of Myasthenia Gravis in a Patient with Chronic Myeloid Leukemia during Treatment with Nilotinib

,
,
and
1
Department of Medicine, Division of Hematology, University of Western Ontario, London, ON N6A 5C1, Canada
2
Department of Oncology, University of Western Ontario, London, ON N6A 5C1, Canada
3
Department of Clinical Neurological Sciences, University of Western Ontario, London, ON N6A 5C1, Canada
*
Author to whom correspondence should be addressed.
Hematol. Rep.2014, 6(2), 5288;https://doi.org/10.4081/hr.2014.5288 
(registering DOI)

Abstract

We report on a patient diagnosed with chronic myeloid leukemia (CML) who developed myasthenia gravis while on treatment with nilotinib. Autoimmune disease, including the development of myasthenia gravis, has been described in association with CML as well as the use of tyrosine kinase inhibitors. Second generation tyrosine kinase inhibitors are highly effective in the treatment of CML, although can result in adverse effects related to off-target kinase inhibition, and longer term reporting of adverse effects is required.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.